1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that Semaglutide offers significant cardiovascular protection beyond its established benefits for weight loss and diabetes management. This establishes Semaglutide as a crucial …
The review identified that GLP-1 RAs exert effects far beyond simple caloric restriction, significantly impacting neural circuits involved in reward processing and impulse control. They found that these agents can mod…
This review provides crucial, actionable guidance that can significantly enhance patient safety and reduce perioperative complications for a rapidly expanding patient population. By differentiating the management stra…
The potential introduction of a high-dose semaglutide (Wegovy HD) could offer a new, more potent option for individuals struggling with obesity who may not achieve sufficient weight loss with current treatments. If th…
While specific quantitative results are not detailed in this summary, the study was designed to rigorously evaluate the efficacy of Liraglutide in a challenging patient population. The primary objective was to determi…
This feasibility study holds significant promise for improving the management of Atrial Fibrillation (AF) in overweight and obese individuals, a population often facing suboptimal outcomes. The key implication is that…
The findings from this study are highly significant for patients managing type 2 diabetes and obesity with Tirzepatide. Knowing that injection site (upper arm, thigh, or abdomen) does not significantly impact drug abs…
This research represents a significant step towards personalized medicine in the treatment of obesity and type 2 diabetes. By understanding the genetic underpinnings of GLP-1 RA response, clinicians could potentially …
This research is significant because it addresses a critical health disparity, focusing on Mexican American women who are at elevated risk for type 2 diabetes. Improving beta cell function is a direct strategy to halt…
If the study's findings demonstrate positive effects on cardio-metabolic risk markers, it would reinforce Liraglutide's role as a multi-faceted treatment, offering significant cardiovascular benefits beyond glucose co…
The study revealed differential impacts on heart failure (HF) risk among incretin-based drug classes. DPP-4 inhibitors were generally associated with a similar risk of HF compared to other oral anti-diabetic drugs; sp…
Understanding the role of hematopoietic stem cells and inflammation in T2D's cardiovascular risk could revolutionize treatment strategies. If semaglutide proves effective in reversing these inflammatory and cellular c…
Understanding the link between neuropathy and semaglutide-induced gastric retention is crucial for optimizing patient care and safety. This research could lead to improved risk stratification for diabetic patients con…
The successful completion of a bioequivalence study is a critical step in the drug development process, particularly for generic versions or new formulations of existing medications. Demonstrating bioequivalence means…
This case report is significant as it highlights a previously unreported dermatological adverse event associated with tirzepatide use. Clinicians prescribing tirzepatide should be aware of SDRIFE as a potential, albei…
This study provides compelling real-world evidence that oral semaglutide not only improves glycemic control and promotes weight loss but also significantly reduces systemic inflammation in patients at high cardiovascu…
This comprehensive analysis strengthens the evidence for Tirzepatide's potential as a multi-organ protective agent, extending its utility beyond metabolic control. The findings suggest that Tirzepatide could be a valu…
This meta-analysis provides compelling evidence of a potential association between GLP-1RA use and an increased risk of NAION, highlighting a crucial ocular safety consideration for millions of patients. Given the wid…
This narrative review is crucial because it synthesizes the current understanding of GLP-1 RAs, suggesting they could be a valuable therapeutic strategy for improving the long-term health of cancer survivors. Given th…
If Liraglutide or Metformin were found to positively influence the telomere-telomerase system or Par-4 in Type 2 Diabetes patients, it would provide novel insights into their mechanisms beyond glucose control. This co…
This comprehensive review underscores the significant potential of liraglutide as an effective therapeutic option for obesity, even in off-label scenarios, providing crucial insights for clinical practice. By synthesi…
This study provides crucial real-world evidence, reinforcing that semaglutide offers significant benefits for patients with type 2 diabetes beyond just managing blood sugar and weight. The observed improvements in kid…
The potential for Liraglutide to address both nicotine dependence and weight management simultaneously is significant, as weight gain is a common barrier to successful smoking cessation. This dual-action approach coul…
This Phase 4 clinical trial provides robust evidence reinforcing that liraglutide, a GLP-1 receptor agonist, is effective in reducing systolic blood pressure in patients with Type 2 diabetes and co-existing hypertensi…
This Phase 1 trial is crucial for understanding the fundamental mechanisms by which liraglutide exerts its metabolic effects in obese individuals, even without specific outcome data in the abstract. By clarifying its …
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study is crucial because it addresses a highly underserved patient group: individuals with severe obesity and multimorbidity who cannot undergo bariatric surgery. The findings could establish a new, effective tre…
The key implication of this research is to understand if Liraglutide, a common Type 2 diabetes medication, offers additional benefits for bone health, which is often compromised in diabetic individuals. If Liraglutide…
This study is significant because it provides valuable real-world data on the long-term effectiveness of Xultophy® in a diverse patient population, complementing controlled clinical trial findings. Understanding how a…
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
This study provides compelling evidence that semaglutide could be a groundbreaking treatment option for individuals struggling with Alcohol Use Disorder, particularly those with comorbid obesity. Given the high global…
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…